Plain-English translation of NCT06735534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The ReMATCH Study is testing the FARAPULSE Pulsed Field Ablation System, a newer catheter-based tool designed to treat persistent atrial fibrillation (an irregular heart rhythm) in patients whose first ablation procedure didn't work. This treatment uses electrical pulses to carefully disable the heart tissue causing the irregular rhythm. The study will enroll about 376 patients and measure whether this approach is safe and effective when used as a second treatment.
Some patients continue to have irregular heartbeats even after their first ablation procedure. This trial exists to see if the newer pulsed field ablation technology can successfully treat these patients who didn't benefit from their initial procedure, offering them another option to restore normal heart rhythm.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a second ablation procedure using the FARAPULSE system at one of the participating medical centers. The procedure works similarly to your first ablation but uses newer pulsed field technology. You will have follow-up visits and heart monitoring to check how well the treatment worked and track your symptoms over time.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States